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Measuring the clinical impact of thoracic computed tomographic scanning Mark 
O Turner
The usefulness of thoracic computed tomographic (CT) there are gold standards (tissue pathology), and haemoptysis illustrate the uncertainties of measuring the clinical scanning in the management and clinical outcome of patients is difficult to measure. Thoracic CT scans are not impact of thoracic CT scanning. stand alone tests but are used in conjunction with other investigations and diagnostic tests. Each of these tests contributes positive or negative information to the clinical Lung malignancy management. A useful diagnostic test is accurate, able to Thoracic CT scanning is commonly used to assess lung facilitate the application of specific treatment, and conmasses or nodules and to stage the extent of mediastinal tributes to a better clinical outcome for the patient. 1 Bedisease. A meta-analysis of 42 studies of lung cancer cause of these characteristics, the impact of diagnostic that staged the mediastinum by CT scanning reported a tests on clinical outcomes is less obvious than therapeutic sensitivity of 0.79 and a specificity of 0.78 for detecting interventions designed to show superiority or equivalence metastatic nodal disease. 7 The sensitivity estimate has been of effect. The greatest impact from CT scanning would be confirmed prospectively by a randomised trial of 685 expected in clinical situations where there is significant patients evaluated for potentially resectable lung cancer. 3 uncertainty about diagnosis, extent of disease, or prognosis. A comparison of management strategies including mediastinAlthough thoracic CT scanning has greater spatial and oscopy versus CT scanning prior to thoracotomy showed a contrast discrimination than chest radiography, more acsensitivity of 0.78 for CT scanning and a slightly lower curate diagnostic information does not always lead to better specificity of 0.69. The primary objective of this multicentre outcomes. New information from a diagnostic test such as Canadian Lung Oncology Group (CLOG) study was to CT scanning may not change procedures or management identify the best strategy to avoid non-curative thoracotomies. plans due to pre-test probabilities that are already high or There were non-significant trends in the CT group for very low. Should CT scans be done when there is a low preventing thoracotomy without cure (relative risk 0.95, 95% likelihood of changing management decisions? In part, this CI 0.75 to 1.19), prevention of thoracotomy for the 45 depends on the accuracy (sensitivity and specificity) of the (6.6%) patients with benign disease (relative risk 0.42, 95% CT scan and whether efficacious treatment exists for a CI 0.12 to 1.13), and a decreased overall cost for services specific clinical problem. The CT diagnosis of pulmonary (mediastinoscopy was more expensive than CT scanning by embolism is a clinical situation where, compared with $708, 95% CI−$723 to $2140). 3 pulmonary angiography, spiral CT scanning is accurate, A randomised trial is a powerful approach to resolving less invasive, less expensive, more widely available, and a controversial clinical question when it has the power leads directly to therapeutic decisions. 2 The role of thoracic to detect a difference. However, as the CLOG study 3 CT scanning for other clinical presentations is less well demonstrates, randomised clinical trials are time condefined.
suming (almost five years from initial recruitment until The optimal assessment of clinical impact is a rancompletion of follow up), costly, and logistically difficult. domised study of CT scanning as an add-on test in similar Although the results of the CLOG study are not definitive, patients and the use of gold standards to determine acthe authors make a reasoned argument for CT scanning curacy. This approach is challenging because of the widefirst, followed by mediastinoscopy, for patients with lymph spread dissemination and acceptance of CT scanning to nodes larger than 1 cm. Several other studies have reinvestigate chest diseases. For example, in a randomised commended mediastinoscopy, even with a negative CT study of CT scanning versus mediastinoscopy for nonscan, because of the relative insensitivity of CT scanning. 8 9 small cell lung cancer, 1120 (42.4%) of the 2639 ineligible In the absence of definitive evidence, many clinicians will patients had already had a CT scan taken or were concontinue to evaluate their patients empirically according to the accessibility of CT scanning and the pattern of sidered to have absolute indications for CT scanning.
3 management particular to their institution. 10 Also, gold standards are not available for many clinical presentations for which thoracic CT scanning is indicated. Most of the data currently available are from retrospective studies on small numbers of patients. 4 Retrospective studies Interstitial lung disease provide weaker evidence for decision making than proThe development of high resolution CT (HRCT) scanning spective studies, partly because of the exclusion of cases has allowed greater accuracy in detecting interstitial lung in which the CT scan result was negative, thus introducing disease and has also identified patterns that are diagnostic. 4 a "verification bias". 5 In a prospective survey of physicians CT scans can impact on clinical management by making ordering thoracic CT scans at a university affiliated tertiary firm diagnoses and therefore avoiding biopsies, by idencare hospital, the most common diagnoses or symptom tifying patients who are likely to respond to treatment, and presentations prior to the scan were lung malignancy, by directing biopsy samples to obtain a maximal yield. interstitial lung disease, bronchiectasis, and haemoptysis. 6 CT scanning demonstrates the extent and location of Haemoptysis is a clinical presentation with no gold standard representative disease more accurately than chest to determine accuracy. Studies of lung cancer with meradiography. 11 12 A radiological/pathological comparison in 458 patients with chronic diffuse infiltrative lung diseases diastinal involvement and interstitial lung disease, where group.bmj.com on July 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from found that 9.6% of chest radiographs taken before the sequently confirmed by CT scanning and the patient had no further bleeding episodes, how is the impact of CT biopsy specimens were interpreted as normal.
13 Direct comparisons between CT scans and chest radiographs for scanning on management measured? A diagnosis of bronchiectasis made after a CT scan may result in fewer indiffuse infiltrative disease, using gold standards of biopsy specimens in most cases, have shown CT scanning to be vestigations and change follow up management, or the extent of the disease may alter a planned surgical procedure. more accurate for the diagnosis and detection of patterns, especially ground glass appearance. 11 14 These outcomes are not reported in Millar's study but are relevant when deciding if thoracic CT scanning is useful Tissue biopsy specimens are taken to make diagnoses and, for some conditions, to establish disease activity. The in the investigation of haemoptysis.
McGuinness and colleagues compared the diagnostic CT scan may also indicate whether a transbronchial biopsy specimen can establish the diagnosis. 11 A study comparing yield from HRCT scans, chest radiographs, and fibreoptic bronchoscopy in 57 consecutive patients with haemotransbronchial biopsy specimens with open lung biopsy specimens in 53 patients with interstitial lung disease ptysis. 21 Eight of the chest radiographs were normal, 38 showed non-localising and 11 localising disease. The CT showed that transbronchial biopsy specimens established a diagnosis in only 20 (38%) while a specific diagnosis was scans were diagnostic in 25% of the normal radiographs, and in 68% of the non-localising and 64% of the localising made with open lung biopsy specimens in 92% of the others. 15 However, there are no prospective or randomised radiographs. The diagnostic yield from fibreoptic bronchoscopy was 43%. The authors recommend HRCT scanstudies to determine the clinical and cost effectiveness of CT scanning before a planned biopsy procedure. In cases ning before bronchoscopy in all patients who present with haemoptysis. The rationale for doing a CT scan first is the where sarcoidosis or lymphangitic carcinomatosis are clinically and radiologically suspected, transbronchial biopsy potential to do fewer bronchoscopies and to guide the bronchoscopist when abnormalities need further evaluspecimens should have a good yield whether or not a CT scan is performed.
ation. 24 It could be argued, however, that neither the study design nor the data support this conclusion, especially in Disease activity, especially when there is evidence of inflammation, can be used to make decisions about inpatients with a normal chest radiograph. The diagnostic yield following CT scanning in this study for patients with stituting treatment. Knowledge of disease activity from a non-invasive diagnostic test such as a CT scan may be a normal radiograph was only 25% compared with 40% for fibreoptic bronchoscopy. important for patients at risk of complications from open biopsies and anti-inflammatory therapy. CT findings of a HRCT scanning was compared with fibreoptic bronchoscopy in 91 patients studied by Set and colleagues. 23 ground glass pattern in patients with cryptogenic fibrosing alveolitis correlated well with four year survival and also
The case mix included 34 (37%) malignancies and 42 (46%) with negative chest radiographs. In the latter group, correlated with response to treatment in a small subgroup of steroid treated patients. 16 The measure of agreement two malignancies were detected by both CT scanning and fibreoptic bronchoscopy. The overall yield in those with a beyond chance (the kappa statistic) was only 0.54 between the two experienced radiologists 16 which raises concerns negative chest radiograph was equivalent, but CT scanning detected bronchiectasis in five patients whereas fibreoptic about how CT scanning would perform in centres with less experienced chest radiologists. In a highly selected bronchoscopy diagnosed bronchitis in four. The investigators recommended CT scanning as an initial ingroup of patients with biopsy proven idiopathic pulmonary fibrosis, chest radiographs and HRCT scans were normal in vestigation for patients with a normal chest radiograph and a low risk for malignancy (age <40, non-smokers), and three of 25 patients with pathological evidence of disease.
17
These three patients were all treated with prednisone and bronchoscopy as the initial investigation for patients suspected of malignancy with a relevant abnormal chest radiocyclophosphamide (two patients) without improvement. Although the patients were symptomatic, intervention at graph. These three prospective studies are consistent in rethis stage seemed to have little impact and suggests that abnormalities on the CT scan which correlate with some commending the use of CT scanning before fibreoptic bronchoscopy in patients with non-massive haemoptysis pulmonary function tests 18 19 are useful in deciding when to intervene medically or surgically.
and normal chest radiographs. [21] [22] [23] These recommendations are based on diagnostic information that may not change or influence management. 25 A randomised trial that measures clinical outcomes and costs for each diagnostic strategy is Haemoptysis Haemoptysis is frequently encountered in a referral setting.
needed to determine the optimal approach to management. After the clinical history and physical examination, chest radiography is the investigation of first choice. An approach taken by several authors is to group the results of chest radiography as localising, non-localising, or normal. 20 
21

Conclusions
Although there have been numerous recommendations to The latter two groups especially merit further investigation, including bronchoscopy to rule out a central malignancy assess prospectively the clinical impact of thoracic CT scanning on patient outcomes, 4 24 26-28 the introduction of and to localise a bleeding site. Three prospective studies have evaluated the role of CT scanning in addition to chest new technology such as spiral CT scanning will lead to another cycle of diagnostic assessment. 29 CT scanning can radiography and fibreoptic bronchoscopy. [21] [22] [23] Millar and colleagues prospectively studied 40 patients certainly impact greatly on the management of individual patients but the appropriate and optimal utilisation for with haemoptysis who had normal chest radiographs and fibreoptic bronchoscopic examinations. 22 Each patient had various clinical presentations needs to be examined more rigorously. In 1976 one of the first clinical evaluations of a contrast enhanced CT scan and abnormalities were found in 20 cases: seven bronchiectasis, four malignancy, one CT scanning used a prospective before and after survey of physicians to measure diagnostic and therapeutic impact. 30 histiocytosis X, one arteriovenous malformation, and six with miscellaneous diagnoses. Although 50% of unBefore and after studies are subject to biases that may affect validity but can generate preliminary results that diagnosed patients had CT abnormalities, the impact of CT scanning on the outcomes is questionable. If bronchiectasis should be confirmed by more rigorous studies. 31 The randomised trial is the optimal methodology to evaluate the was the working diagnosis prior to the CT scan, sub- 
